Area of research
Molecular Biology · Oncology
Research interest
Research focused on Dabrafenib and Dacarbazine, with related work in Metastatic melanoma, Trametinib, Melanoma. Notable publications include 'Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial', 'BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF -Mutant Thyroid Cancer', and 'Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial'.
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials
Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program
BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i> -Mutant Thyroid Cancer
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial
An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAF<sup>V600E</sup>-mutated melanoma.